

Shivani Srivastava

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11225721/publications.pdf>

Version: 2024-02-01

20
papers

2,714
citations

840776

11
h-index

839539

18
g-index

20
all docs

20
docs citations

20
times ranked

3891
citing authors

#	ARTICLE	IF	CITATIONS
1	Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. <i>New England Journal of Medicine</i> , 2022, 386, 24-34.	27.0	766
2	Engineering CAR-T cells: Design concepts. <i>Trends in Immunology</i> , 2015, 36, 494-502.	6.8	354
3	CCR7 provides localized access to IL-2 and defines homeostatically distinct regulatory T cell subsets. <i>Journal of Experimental Medicine</i> , 2014, 211, 121-136.	8.5	345
4	Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. <i>Journal of Clinical Investigation</i> , 2016, 126, 4262-4272.	8.2	229
5	T-bet+ Treg Cells Undergo Abortive Th1 Cell Differentiation due to Impaired Expression of IL-12 Receptor $\beta 2$. <i>Immunity</i> , 2012, 37, 501-510.	14.3	218
6	Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting. <i>Cancer Cell</i> , 2019, 35, 489-503.e8.	16.8	218
7	Regulatory T cell homeostasis: steady-state maintenance and modulation during inflammation. <i>Immunological Reviews</i> , 2014, 259, 40-59.	6.0	177
8	Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade. <i>Cancer Cell</i> , 2021, 39, 193-208.e10.	16.8	157
9	Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy. <i>Journal of Immunology</i> , 2018, 200, 459-468.	0.8	155
10	Prophylaxis with Sirolimus and Tacrolimus \pm Antithymocyte Globulin Reduces the Risk of Acute Graft-versus-Host Disease without an Overall Survival Benefit Following Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 916-922.	2.0	30
11	Peripheral Blood Stem Cell Mobilization Tactics. <i>Annals of Pharmacotherapy</i> , 2010, 44, 107-116.	1.9	25
12	A Phase I Trial of High-Dose Clofarabine, Etoposide, and Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation in Patients with Primary Refractory and Relapsed and Refractory Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 987-994.	2.0	11
13	Possible Correlation of Sirolimus Plasma Concentration with Sinusoidal Obstructive Syndrome of the Liver in Patients Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation. <i>Pharmacotherapy</i> , 2012, 32, 441-445.	2.6	9
14	Experience with Plerixafor for Hematopoietic Cell Mobilization in Nine Patients with Germ Cell Tumors. <i>Pharmacotherapy</i> , 2014, 34, 85-88.	2.6	8
15	Enhancing Natural Killer (NK) Cell Mediated Killing of Non-Hodgkin's Lymphoma.. <i>Blood</i> , 2009, 114, 2706-2706.	1.4	5
16	Special delivery! CAR-T cells transport RN7SL1 to the tumor microenvironment. <i>Trends in Molecular Medicine</i> , 2021, 27, 1019-1021.	6.7	4
17	A Phase I Trial of High-Dose Clofarabine, Etoposide, and Cyclophosphamide: A Novel Preparative Regimen Prior to Autologous Peripheral Blood Stem Cell (PBSC) Transplantation in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma.. <i>Blood</i> , 2009, 114, 3402-3402.	1.4	2
18	Phase I Trial of High-Dose Clofarabine and Busulfan as a Myeloablative Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Leukemia.. <i>Blood</i> , 2009, 114, 198-198.	1.4	1

#	ARTICLE	IF	CITATIONS
19	Costimulatory Effects of Interleukin-18 (IL-18) on Human Natural Killer (NK) Cells Activated through Fc Receptors for Immunoglobulin (IgG). Blood, 2010, 116, 2780-2780.	1.4	0
20	Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, and Pure Red Cell Aplasia. , 0, , 189-196.		0